Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Accepted Manuscript] Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis

Autor: Molloy, S.F., Bradley, J., Karunaharan, N., Mputu, M., Stone, N., Phulusa, J., Chawinga, C., Gaskell, K., Segula, D., Ming, D., Peirse, M., Chanda, D., Lakhi, S., Loyse, A., Kanyama, C., Heyderman, R.S., Harrison, T.S.

We assessed the effect of fluconazole 1200 mg/day on QT interval in cryptococcal meningitis patients. Mean QTc change from baseline to day 7 was 10.1ms (IQR: -28 to 46) in the fluconazole treatment group and -12.6ms (IQR: -39 to 13.5) in those not ta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::94566023cfaf716479da830b93581b4e

A randomized controlled trial for the treatment of HIV-associated cryptococcal meningitis in Africa: oral fluconazole plus flucytosine or one week amphotericin-based therapy versus two weeks amphotericin-based therapy. The ACTA Trial

Autor: Molloy, S, Kanyama, C, Heyderman, R, Loyse, A, Kouanfack, C, Chanda, D, Mfinanga, S, Temfack, E, Lakhi, S, Lesikari, S, Chan, A, Stone, N, Kalata, N, Karunaharan, N, Gaskell, K, Peirse, M, Ellis, J, Chawinga, C, Lontsi, S, Ndong, J-G, Bright, P, Lupiya, D, Chen, T, Bradley, J, Adams, J, van der Horst, C, van Oosterhout, JJ, Sini, V, Mapoure, YN, Mwaba, P, Bicanic, T, Lalloo, D, Wang, D, Hosseinipour, M, Lortholary, O, Jaffar, S, Harrison, T, Team, ACTATS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::f6d2ef2fb7dea7a4c77e5d04a2441c30
https://openaccess.sgul.ac.uk/id/eprint/109077/1/22253-31333-1-PB-MOAX0201LB.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

Autor: Agnandji, ST, Lell, B, Fernandes, JF, Abossolo, BP, Kabwende, AL, Adegnika, AA, Mordmueller, B, Issifou, S, Kremsner, PG, Loembe, MM, Sacarlal, J, Aide, P, Madrid, L, Lanaspa, M, Mandjate, S, Aponte, JJ, Bulo, H, Nhama, A, Macete, E, Alonso, P, Abdulla, S, Salim, N, Mtoro, AT, Mutani, P, Tanner, M, Mavere, C, Mwangoka, G, Lweno, O, Juma, OA, Shekalaghe, S, Tinto, H, D'Alessandro, U, Sorgho, H, Valea, I, Ouedraogo, JB, Lompo, P, Diallo, S, Traore, O, Bassole, A, Dao, E, Hamel, MJ, Kariuki, S, Oneko, M, Odero, C, Otieno, K, Awino, N, Muturi-Kioi, V, Omoto, J, Laserson, KF, Slutsker, L, Otieno, W, Otieno, L, Otsyula, N, Gondi, S, Otieno, A, Ogutu, B, Ochola, J, Onyango, I, Oyieko, J, Njuguna, P, Chilengi, R, Akoo, P, Kerubo, C, Maingi, C, Olotu, A, Bejon, P, Marsh, K, Mwabingu, G, Gitaka, J, Owusu-Agyei, S, Asante, KP, Boahen, O, Dosoo, D, Adjei, G, Adeniji, E, Yawson, AK, Kayan, K, Chandramohan, D, Greenwood, B, Lusingu, J, Gesase, S, Malabeja, A, Abdul, O, Mahende, C, Liheluka, E, Lemnge, M, Theander, TG, Drakeley, C, Mbwana, J, Ansong, D, Agbenyega, T, Adjei, S, Boateng, HO, Rettig, T, Bawa, J, Sylverken, J, Sambian, D, Sarfo, A, Agyekum, A, Martinson, F, Hoffman, I, Mvalo, T, Kamthunzi, P, Nkomo, R, Tembo, T, Tsidya, GTM, Kilembe, J, Chawinga, C, Ballou, WR, Cohen, J, Guerra, Y, Jongert, E, Lapierre, D, Leach, A, Lievens, M, Ofori-Anyinam, O, Olivier, A, Vekemans, J, Kaslow, D, Leboulleux, D, Savarese, B, Schellenberg, D, Partnership, RTSSCT

Publikováno v: PLoS Medicine
PLoS Medicine, Vol 11, Iss 7, p e1001685 (2014)

Mary Hamel and colleagues in the RTS,S Clinical Trials Partnership report updated safety and efficacy results from an ongoing Phase 3 trial, including calculations of vaccine impact (malaria cases prevented). Please see later in the article for the E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6236e8cf4d7a1ce20ddc0ba7bb18b40
http://europepmc.org/articles/PMC4114488